<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Thu, 26 Feb 2026 16:01:00 -0500</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  &lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;TD Cowen 46th Annual Health Care Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/04/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Barclays 28th Annual Global Healthcare Conference&lt;/strong&gt;&lt;br/&gt;Date: 03/10/26&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Leerink Partners Global Healthcare Conference 2026&lt;/strong&gt;&lt;br/&gt;Date: 03/11/26&lt;/p&gt;  &lt;p&gt;Interested parties can register for and access the live webcast for the conferences by visiting the “&lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=69m7PUISEyqC8KlZ-FvOUSiWnuiOU6hGhhMwgIUVielR61kqWyOkj2uE3qCW6HHXEjUyiz_It5fEzey2OyJQaq8BskOl7WYb8E1fsJVV8tK74Rg8k8rdJThMAnDCmUPs&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Events&lt;/a&gt;” section of the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+Three+Upcoming+Investor%C2%A0Conferences%C2%A0/26070214.html</guid>
   <pubDate>Thu, 26 Feb 2026 16:01:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50100012</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07579093</category>
   	  </item>
  <item>
   <title>Cardiff Oncology (CRDF) PT Lowered to $6 at Piper Sandler</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Cardiff+Oncology+%28CRDF%29+PT+Lowered+to+%246+at+Piper+Sandler/26056000.html</link>
   <description>Piper Sandler analyst Edward Tenthoff lowered the price target on Cardiff Oncology (NASDAQ: CRDF) to $6.00  (from $10.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Cardiff+Oncology+%28CRDF%29+PT+Lowered+to+%246+at+Piper+Sandler/26056000.html</guid>
   <pubDate>Wed, 25 Feb 2026 08:47:55 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	  </item>
  <item>
   <title>Form  8-K        Cardiff Oncology, Inc.    For: Feb 25</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+25/26055862.html</link>
   <description>si-local-file:///var/storage/secattach/20260225/26055862.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+25/26055862.html</guid>
   <pubDate>Wed, 25 Feb 2026 08:31:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	  </item>
  <item>
   <title>Form  8-K        Cardiff Oncology, Inc.    For: Feb 25</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+25/26055862.html</link>
   <description>si-local-file:///var/storage/secattach/20260225/26055862.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+25/26055862.html</guid>
   <pubDate>Wed, 25 Feb 2026 08:31:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	  </item>
  <item>
   <title>Form  8-K        Cardiff Oncology, Inc.    For: Feb 24</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+24/26052928.html</link>
   <description>si-local-file:///var/storage/secattach/20260224/26052928.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+24/26052928.html</guid>
   <pubDate>Tue, 24 Feb 2026 17:10:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	  </item>
  <item>
   <title>Form  8-K        Cardiff Oncology, Inc.    For: Feb 24</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+24/26052928.html</link>
   <description>si-local-file:///var/storage/secattach/20260224/26052928.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Feb+24/26052928.html</guid>
   <pubDate>Tue, 24 Feb 2026 17:10:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	  </item>
  <item>
   <title>Form  10-K       Cardiff Oncology, Inc.    For: Dec 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Cardiff+Oncology%2C+Inc.++++For%3A+Dec+31/26052900.html</link>
   <description>si-local-file:///var/storage/secattach/20260224/26052900.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Cardiff+Oncology%2C+Inc.++++For%3A+Dec+31/26052900.html</guid>
   <pubDate>Tue, 24 Feb 2026 17:08:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	  </item>
  <item>
   <title>Form  10-K       Cardiff Oncology, Inc.    For: Dec 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Cardiff+Oncology%2C+Inc.++++For%3A+Dec+31/26052900.html</link>
   <description>si-local-file:///var/storage/secattach/20260224/26052900.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Cardiff+Oncology%2C+Inc.++++For%3A+Dec+31/26052900.html</guid>
   <pubDate>Tue, 24 Feb 2026 17:08:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
  <item>
   <title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)&lt;br/&gt;&lt;/em&gt;&lt;em&gt;• Significant improvement in PFS over combined SoC (HR: 0.37, p&amp;lt;0.05)&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026&lt;/em&gt;&lt;/p&gt;  &lt;p&gt;SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Reports+Full+Year+2025+Results+and+Provides+Business+Update/26052135.html</guid>
   <pubDate>Tue, 24 Feb 2026 16:30:00 -0500</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216399</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CRDF</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687800</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22795517</category>
   	  </item>
 </channel>
</rss>
